SCHEMBL3130997

SCHEMBL3130997

O=C(O)Cc1ccc(N(Cc2cnccn2)c2ccc(OC(F)F)c(OC(F)F)c2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 8/20 0.42
KMT2A Q03164 1/20 0.37
HDAC1 Q13547 1/20 0.37
GAA P10253 1/20 0.37
PDE4B Q07343 4/20 0.36
PDE4C Q08493 4/20 0.36
PDE4D Q08499 4/20 0.36
RORC P51449 1/20 0.35
PTGDR2 Q9Y5Y4 2/20 0.35
FGFR1 P11362 1/20 0.34
FGFR2 P21802 1/20 0.34
FGFR4 P22455 1/20 0.34
FGFR3 P22607 1/20 0.34
KDR P35968 1/20 0.34
TDP1 Q9NUW8 1/20 0.33
FNTA P49354 1/20 0.33
FNTB P49356 1/20 0.33
GRIN1 Q05586 1/20 0.33
GRIN2B Q13224 1/20 0.33
RXRA P19793 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3120621 0.88 PDE4A (0.40) PDE4AHDAC1GAAPDE4BPDE4C
SCHEMBL3215675 0.88 GAA (0.38) KMT2AHDAC1GAAPTGDR2FGFR1
SCHEMBL3131421 0.86 SYK (0.45) PDE4AKMT2AHDAC1GAAPDE4B
SCHEMBL3132242 0.86 FGFR1 (0.35) PDE4AHDAC1GAAPDE4BPDE4C
SCHEMBL3126203 0.85 NAPRT (0.46) PDE4AKMT2APDE4BPDE4CPDE4D
SCHEMBL3126333 0.83 RXRA (0.48) PDE4AGAAPDE4BPDE4CPDE4D
SCHEMBL3128465 0.83 PDE4A (0.44) PDE4AGAAPDE4BPDE4CPDE4D
SCHEMBL3132484 0.83 PDE4D (0.39) PDE4AKMT2AGAAPDE4BPDE4C
SCHEMBL3122655 0.82 SYK (0.40) KMT2AGAAFGFR1FGFR2FGFR4
SCHEMBL3132346 0.82 SYK (0.40) KMT2AGAAFGFR1FGFR2FGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US claimed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed
WO-2010003084-A2 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029689-A1 PHOSPHODIESTERASE 4 INHIBITORS PDE4A, PDE4B, PDE3B PDE4A 1/4885KMT2A 1324/4885HDAC1 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.